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Statement of translational relevance 
The observed differences in IgG glycome composition between patients and controls 
could potentially have relevance as a biomarker in the general population, especially 
if incorporated with other variables into risk profiling algorithms, have relevance to 
surveillance in subjects at high risk due to germline mutations, such as in Lynch 
Syndrome.  Our findings also suggest that genetic factors influencing glycome 
composition could be explored as risk factors for colorectal cancer. Finally, glyco-
modifications might have relevance to tumour immunosurveilance and in predicting 
response to monoclonal antibodies. 
 
Abstract (250 words) 
 
Purpose: Alternative glycosylation has significant structural and functional 
consequences on immunoglobulin G and consequently also cancer 
immunosurveilance. Due to technological limitations, the effects of highly heritable 
individual variations and the differences in the dynamics of changes in IgG 
glycosylation on colorectal cancer (CRC) were never investigated before.  
Experimental design: Using recently developed high-throughput UPLC technology 
for IgG glycosylation analysis we analysed IgG glycome composition in 760 patients 
with CRC and 538 matching controls. Effects of surgery were evaluated in 28 patients 
sampled before and three times after surgery. A predictive model was built using 
regularized logistic regression and evaluated using a 10-cross validation procedure. 
Furthermore, IgG glycome composition was analysed in 39 plasma samples collected 
before initial diagnosis of CRC. 
Results: We have found that CRC associates with decrease in IgG galactosylation, IgG 
sialylation and increase in core-fucosylation of neutral glycans with concurrent 
decrease of core fucosylation of sialylated glycans. While a model based on age and 
sex did  not  show discriminative power (AUC=0.499), the addition of glycan variables 
into the model considerably increased the discriminative power of the model 
(AUC=0.755). However, none of these differences were significant in the small set of 
samples collected before the initial diagnosis. 
Conclusions: Considering the functional relevance of IgG glycosylation for both 
tumour immunosurveilance and clinical efficacy of therapy with monoclonal 
antibodies, individual variation in IgG glycosylation may turn out to be important for 
prediction of disease course or the choice of therapy, thus warranting further, more 








The majority of extracellular and secreted proteins are post-translationally modified 
by the addition of glycans that are important structural and functional elements in 
the majority of biological processes (1). A recent comprehensive report endorsed by 
the US National Academies concluded that “glycans are directly involved in the 
pathophysiology of every major disease” and that “additional knowledge from 
glycoscience will be needed to realize the goals of personalized medicine and to take 
advantage of the substantial investments in human genome and proteome research 
and its impact on human health” (2). Glycans seem to have a particularly important 
role in the immune system and inter-individual variation in glycosylation may affect 
function of the immune system on multiple levels (3).  The differences in an 
individual's immune repertoire and the capacity to process and present antigens are 
an important element of cancer immunosurveilance (4, 5). In addition to natural 
anti-cancer antibodies, therapeutic antibodies provide clinical benefit to patients 
with cancer and have been established as 'standard of care' therapy for several 
highly prevalent human cancers (6). While antigen specificity of antibodies is 
determined by nucleotide sequence of hypervariable regions, effector functions of 
antibodies are largely determined by alternative glycosylation of asparagine 297 in 
the Fc region of IgG (7, 8). Depending on the extent of galactosylation, sialylation 
and fucosylation of its glycans, IgG will activate complement, activate antibody-
dependent cellular cytotoxicity (ADCC), or even have an anti-inflammatory action (9, 
10). Both ADCC and complement-dependent cytotoxicity are important for function 
of anti-cancer antibodies (6), thus variation in IgG glycosylation may influence inter-
individual variability in cancer immunosurveilance and/or response to therapeutic 
antibodies. 
Our recent studies demonstrated that IgG glycosylation is very variable between 
individuals (11), but the functional relevance of this variation is not known. Since 
glycans do not have a direct genetic template, glycan structures that will be attached 
to an individual protein are determined by complex dynamic interactions between a 
number of genetic and environmental factors (12). Our recent studies have revealed 
that genetic loci associated with variation in IgG glycosylation are also known risk 
factors for several autoimmune diseases and cancers (13), indicating that variations 
in IgG function may be one of the mechanisms linking these genetic loci and 
diseases. Further support for this hypothesis came from recent large case / control 
studies that reported significantly reduced immunosuppressive features of IgG 
glycome in inflammatory bowel disease (14) and systemic lupus erythematous (15). 
In this study we have compared IgG glycosylation in 760 patients with colorectal 
cancer (CRC) with that in 538 age and sex matched healthy controls. Effects of 
surgery on IgG glycome were evaluated in 28 patients sampled before surgery, and 
at three additional time points after surgery. Furthermore, we identified 39 historical 
samples of people who subsequently developed CRC and compared their IgG 
glycome composition to matched controls (80 individuals that did not develop CRC 




Materials and methods 
 
Study population 
The Study of Colorectal Cancer in Scotland (SOCCS) study (1999-2006) is a case-
control study designed to identify genetic and environmental factors associated with 
non-hereditary colorectal cancer risk and survival outcomes. Approval for the study 
was obtained from the MultiCentre Research Ethics Committee for Scotland and 
Local Research Ethics committee, and all participants gave written informed consent. 
The study has been described in detail elsewhere(16).  
The present study includes a subset of 760 patients with pathologically confirmed 
colorectal adenocarcinoma and 538 matching controls. IgG glycome composition 
was analysed in samples collected after CRC diagnosis or recruitment. Participants 
completed a detailed lifestyle questionnaire, a semi-quantitative food frequency 
(http://www.foodfrequency.org) and supplements questionnaire. Blood was 
collected and transferred to the research centre within 72 h of sampling. Plasma was 
prepared from whole blood by gentle centrifugation through a ficoll-hypaque 
gradient and 1.5 mL of each participant’s plasma was stored at -80°C. 
Effects of surgery on the IgG glycome were evaluated in 28 patients sampled before 
surgery, 24h, 48h and 7 days after surgery. Samples were collected at the Clinical 
Department for Laboratory Diagnostics at University Hospital Dubrava, The study 
was registratated at ClinicalTrials.gov, number NCT01244022 and was approved by 
the Ethics Committee of University Hospital Dubrava.  
Patients who were sampled before the initial diagnosis of CRC, as well as matching 
controls that did not develop CRC during the same follow-up time were selected 
from the FINNRISK cohort (17). 
Isolation of IgG from human plasma  
The IgG was isolated using protein G monolithic plates (BIA Separations, Ajdovščina, 
Slovenia) as described previously (11).Briefly, 70 - 100 µl of plasma was diluted 8× 
with 1× PBS, pH 7.4, applied to the protein G plate and instantly washed with 1× PBS, 
pH 7.4 to remove unbound proteins. IgGs were eluted with 1 ml of 0.1 M formic acid 
(Merck, Darmstadt, Germany) and neutralized with 1 M ammonium bicarbonate 
(Merck, Darmstadt, Germany).  
Glycan release  
IgG samples were dried in a vacuum concentrator, dissolved in 30 μL 1.33% SDS 
(w/v) (Invitrogen, Carlsbad, CA, USA) and denatured by incubation at 65 °C for 10 
minutes. After incubation, samples were left to cool down to room temperature for 
30 minutes. Subsequently, 10 μL of 4% Igepal-CA630 (Sigma-Aldrich, St. Louis, MO, 
USA) were added to the samples and incubated on a shaker for 15 minutes.  After 
shaking, 1.25 mU of PNGase F (ProZyme, Hayward, CA, USA) in 10 μL 5× PBS were 
added and incubated overnight at 37 °C for N-glycan release.  
Glycan labelling 
The released N-glycans were labelled with 2-aminobenzamide (2-AB). The labelling 
mixture was freshly prepared by dissolving 2-AB (Sigma-Aldrich, St. Louis, MO, USA) 
in DMSO (Sigma-Aldrich, St. Louis, MO, USA) and glacial acetic acid (Merck, 
Darmstadt, Germany) mixture (70:30, v/v) and by adding 2-picoline borane (Sigma-
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Aldrich, St. Louis, MO, USA) to a final concentration of 19.2 mg/mL for 2AB and 44.8 
mg/ml for 2-picoline borane. A volume of 25 μL of labelling mixture was added to 
each N-glycan sample in the 96-well plate and the plate was sealed using adhesive 
tape. Mixing was achieved by shaking for 10 minutes, followed by 2 hour incubation 
at 65 °C.  
HILIC-SPE 
Free label and reducing agent were removed from the samples using HILIC-SPE. 
Cellulose based HILIC SPE clean-up of the Hispanic cohort samples was performed as 
described previously (Kristic et al., 2014). The 2x 100 μL eluates were combined and 
stored at –20 °C until usage. 
Hydrophilic Interaction Chromatography (HILIC)-UPLC 
Fluorescently labelled N-glycans were separated by hydrophilic interaction 
chromatography on a Waters Acquity UPLC instrument (Milford, MA, USA) consisting 
of a quaternary solvent manager, sample manager and a FLR fluorescence detector 
set with excitation and emission wavelengths of 250 and 428 nm, respectively. The 
instrument was under the control of Empower 2 software, build 2145 (Waters, 
Milford, MA, USA). Labelled N-glycans were separated on a Waters BEH Glycan 
chromatography column, 100 × 2.1 mm i.d., 1.7 μm BEH particles, with 100 mM 
ammonium formate, pH 4.4, as solvent A and acetonitrile as solvent B. Separation 
method used linear gradient of 75–62% acetonitrile (v/v) at flow rate of 0.4 ml/min 
in a 25 minute analytical run. Samples were maintained at 5 °C before injection, and 
the separation temperature was 60 °C. The system was calibrated using an external 
standard of hydrolyzed and 2-AB labelled glucose oligomers from which the 
retention times for the individual glycans were converted to glucose units. Data 
processing was performed using an automatic processing method with a traditional 
integration algorithm after which each chromatogram was manually corrected to 
maintain the same intervals of integration for all the samples. The chromatograms 
were all separated in the same manner into 24 peaks and the amount of glycans in 
each peak was expressed as % of total integrated area.  
 
Statistical analysis 
Clinical characteristics among patients and controls were compared using Wilcoxon 
and Fisher Exact tests. To make measurements across samples comparable, 
normalization by total area was performed where peak area of each of 24 glycan 
structures was divided by total area of corresponding chromatogram. Batch 
correction was performed on normalized log-transformed measurements using 
linear mixed models (R package lme4), where technical source of variation was 
modelled as random effect. In addition to 24 directly measured glycan structures, 12 
derived traits were calculated from the directly measured glycans. These derived 
traits average particular glycosylation features (galactosylation, fucosylation, 
sialylation) across different individual glycan structures and consequently they are 
more closely related to individual enzymatic activities and underlying genetic 
polymorphisms.  
Association analyses between disease status and glycan traits were performed using 
a logistic regression model with age and sex included as additional covariates. Prior 
to analyses, glycan variables were all transformed to standard Normal distribution 
 6
(mean=0,sd=1) by inverse transformation of ranks to Normality (R package 
"GenABEL", function rntransform). Using rank transformed variables in the analysis 
makes estimated odds ratios of different glycans comparable as transformed glycan 
variables have the same standardized variance, and in that case estimated odds 
ratios always correspond to one standard deviation change in the measured glycan 
trait. False discovery rate was controlled using Benjamini-Hochberg procedure (18).  
 
For prediction of CRC status, regularized logistic (elastic net) regression model was 
applied (R package "glmnet"). For classification, only 24 initial glycan traits were 
used as predictors. Prior to model training and validation, elastic net regularization 
parameters (alpha and lambda) were tuned on 20% of samples (260 samples), and 
optimal parameters chosen by the tuning procedure (alpha = 0, lambda = 0.1) were 
used in further analysis. To evaluate performance of predictive model 10-cross 
validation procedure was used on remaining 80% of samples. Predictions from each 
validation round were merged into one validation set on which model performance 
was evaluated based on area under the receiver operating characteristic curve (AUC) 
criteria. The AUCs of different models were compared using a bootstrap test. 
 
Data was analyzed and visualized using R programming language (version 3.0.1). 
 
Expression datasets for colorectal carcinoma 
Expression data for colorectal carcinoma were downloaded from the Gene 
Expression Omnibus (GEO) database (19). We picked datasets with a comparably 
large number of samples (49 to 148 samples total) that included both colorectal 
cancer and the matching non-cancerous tissue. The datasets are stored under the 
accession numbers GSE8671(20), GSE21510 (21) and GSE24514 (22). 
 
Analysis of gene expression in colorectal carcinoma 
Expression data analysis was conducted using the R language and environment for 
statistical computing (23), which was also used for preparation of figures. Data were 
retrieved with the R package “GEOquery”. Differences in expression levels with the 
corresponding p-values for each dataset containing cancer and non-cancer samples 
were calculated using the package “limma”. Genes were annotated according to the 
package and database “org.Hs.eg.db”. Results for the 20 selected candidate genes 
were visualized as volcano plots constructed with the aid of the package “ggplot2”. 
In these plots, the cut-off value for significance was set well above the level of 
p=0.05 adjusted using Bonferroni correction for multiple testing. The cut-off value 
for the fold change was picked for each individual dataset such that only the several 







IgG glycome composition was analysed in 760 patients with CRC and 538 matching 
controls. Descriptive information on CRC patients and healthy controls are presented 
in Table 1.  Total IgG glycome (combined Fc and Fab glycans) composition was 
determined by UPLC analysis of 2AB-labelled glycans as reported recently (13). A 
typical chromatogram showing separation of the IgG glycome into individual 
structures is shown in Fig 1. Many of these structures share the same structural 
features (galactose, sialic acid, core-fucose), thus additional derived traits were 
calculated that average these features across multiple glycans (Supplementary Table 
1). 
Significant differences were observed in several features of the glycome (Table 2, Fig 
2), primarily reflecting decreased galactosylation (OR=2.35, p=2.39E-22 for G0 and 
OR=0.36, p=6.59E-29 for G2) and sialylation (OR=0.72, p=2.73E-05 for S total), as well 
as increased fucosylation of neutral IgG glycans (OR=1.24, p=3.57E-03 for F total) and 
decreased fucosylation of sialylated glycans (OR=0.72, p=5.85E-05 for F sialo). As 
many glycan structures showed strong association with CRC, we attempted to build a 
predictive model using regularized logistic regression. Only the 24 directly measured 
glycan traits were used as predictors in the model. Evaluation of model performance 
was conducted using a 10-cross validation procedure. While a model based  on  age  
and  sex  did  not  show significant discriminative power (AUC = 0.499), the addition 
of glycan variables into the model considerably increased the discriminative power 
of the model (AUC = 0.755, P < 1x10E-16)(Fig 3).  
Glycome composition is known to change in acute inflammation (24) and to evaluate 
potential effects of surgery on the IgG glycome in CRC patients we analysed IgG 
glycome composition in 28 patients (i) before surgery, (ii) 24 after surgery), (iii) 48 h 
after surgery and (iv) 7 days after surgery. We did not observe any consistent and 
statistically significant changes in the IgG glycome that were caused by the surgery 
(data not shown). 
To determine whether the observed changes were present before the disease onset, 
we identified 39 individuals from the FINNRISK cohort that were sampled before the 
initial diagnosis. However, when compared to matching controls, no statistically 
significant changes were found.  
Core-fucose is added to glycans by the fucosyltransferase 8 enzyme (encoded by 
FUT8 gene), which has recently been reported to be functionally relevant in some 
cancers (25-27). Aiming to investigate the potential molecular mechanisms 
underlying increased IgG core-fucosylation in CRC, we examined effects of single 
nucleotide polymorphisms (SNPs) that associated with fucose-related glycan traits 
on both glycans and CRC. A list of SNPs that showed the strongest associations with 
fucosylation in our recent IgG glycome GWAS are shown in Supplementary table 3 
with effect sizes and p values for both glycans and CRC. Although SNPs that associate 
with fucosylation did not pass correction for multiple testing for association with 
CRC, it is of interest that we observed nominally significant associations with CRC risk 
for 96 out of 100 top glycan SNPs and that the direction of the effect was consistent 
for both core fucose and CRC risk in all these SNPs.  
 
 8
Furthermore, we examined the expression of all genes that were previously 
associated with the IgG glycome (13) in CRC and matching tissues in publicly 
available datasets. Significantly increased expression of FUT8 was observed in all 







This study represents the first comprehensive analysis of IgG glycosylation in 
colorectal cancer. By applying the recently developed method for high-throughput 
glyco-profiling of IgG (11) on a well-characterized large cohort of CRC patients and 
matching controls we have filled this important gap in knowledge which may have 
relevance for understanding the immunosurveilance of CRC (4). More generally, 
given the established role of IgG glycan composition in determining IgG effector 
function, these data may be of importance in helping to understand determinants of 
success of anti-cancer therapy with monoclonal antibodies (6). By analysing 760 CRC 
patients and 538 matching controls we have found that CRC is associated with three 
major alterations in the IgG glycome composition: (i) decrease in IgG galactosylation, 
(ii) decrease in IgG sialylation and (iii) increase in core-fucosylation of neutral glycans 
with concurrent decrease of core fucosylation of sialylated glycans. 
The addition of galactose and sialic acid to IgG glycans have been shown to result in 
the conversion of pro-inflammatory activity of IgG into an anti-inflammatory activity 
and are believed to be essential for the immunosuppressive activity of intravenously 
administered immunoglobulins (IVIG) (28). Galactosylation and sialylation of IgG 
decrease significantly with the age of an individual (29). The same pattern of changes 
in the IgG glycome have been reported in rheumatoid arthritis (30), osteoarthritis 
(30), inflammatory bowel disease (14, 31), systemic lupus erythematosus (15) and 
some other diseases (32). In this study we have observed consistent decreases in all 
structures with two terminal galactoses (A2BG2 (GP13), FA2G2 (GP14) and 
FA2BG2(GP15)) and an increase in structures without galactoses (A2 (GP2), A2B 
(GP3), FA2 (GP4) and FA2B (GP6)) (Supplementary Table 2). The decrease in 
galactosylation was also evident in the derived traits G0 and G2 that average 
galactosylation in several individual glycans (G0: OR=2,35; p =2,39E-22; G2: OR=0,36; 
p=6,59E-29). Several directly measured IgG glycans containing sialic acid, as well as 
the derived trait “S1 total” (measuring all monosialylated IgG glycans) were also 
decreased in CRC patients (Table 2). 
Since decreases in galactosylation and sialylation have also been observed in a 
number of other diseases (32), this pattern of glycan changes (which are consistent 
with a decrease in the immunosuppressive potential of IgG) is not specific for CRC. 
Since little is known about the mechanisms of regulation of IgG glycosylation (12) it 
is very difficult to speculate about potential mechanisms and causes of these 
differences. The heritability of IgG glycosylation is relatively high. The heritability of 
galactosylation has been estimated to be between 40% and 70% and of sialylation 
between 30% and 60% (11, 33). However, the glycome has also been reported to be 
dynamic and capable of change (particularly in situations of disturbed homeostasis 
(24). Recently it was reported that the IgG glycome changes before the onset of 
rheumatoid arthritis (34, 35), indicating that they may be a part of disease 
pathophysiology. In an analogous attempt to address causality in this study we were 
able to identify 39 individuals that were sampled before the initial diagnosis of CRC. 
However, when compared to matching controls (individuals of the same age that did 
not develop CRC in the same period after recruitment) we did not identify any 
statistically significant differences. Since the sample size was very small it is hard to 
derive any conclusions from this exploratory part of the study, beside the fact that 
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we were not able to show any differences in IgG glycome composition before the 
onset of CRC. 
Activation of ADCC is believed to be an important mechanism of therapeutic 
monoclonal antibodies, as indicated by the fact that a common single-nucleotide 
polymorphism in FcγRIIIa (V158F) is correlated with clinical responses to cetuximab 
(36) and rituximab (37). The attachment of fucose to the glycan core (core-fucose) is 
a mechanism that interferes with binding of IgG to FcγRIIIa and greatly diminishes its 
capacity to activate ADCC (38, 39).  The removal of core-fucose from IgG glycans 
increases clinical efficacy of monoclonal antibodies, enhancing their therapeutic 
effect through ADCC mediated killing (40-42). Recently it has been shown that 
properly glyco-engineered antibodies (43) can efficiently elicit ADCC even in 
immunocompromised CRC patients (44). This observation indicates that efficient 
immunosurveilance of tumor cells depends on antibody/Fc receptor affinity. Thus, 
increased levels of core-fucose on neutral IgG glycans in CRC patients may influence 
disease risk and course by decreasing the ability of IgG to activate ADCC.  
Interestingly, core-fucose was increased in sialylated glycans. To the best of our 
knowledge this is the first report of different direction of changes in fucosylation in 
sialylated and neutral glycans. Recent studies clearly demonstrated that some 
antigen-specific antibodies can have significantly different levels of fucose (45), but it 
is hard to evaluate the importance in the different fucosylation of sialylated and 
neutral IgGs, since the relevance of sialylation on the impact of fucose on IgG 
function is currently not known (46).  
This is further supported by the observation that polymorphisms in the FUT8 gene 
seem to be associated with increased risk for CRC. In our relatively small dataset this 
association did not remain statistically significant after correction for multiple 
testing. Nevertheless, we suggest that this is an interesting and potentially important 
observation. It is supported by our finding that 96 out of 100 top glycan SNPs were 
also nominally significant for CRC risk, with directions of effect that were consistent 
(Supplementary Table 1) with our hypothesis. A larger study would be needed to 
confirm this association, but if replicated, this observation would indicate that 
individual variation in IgG fucosylation affects risk for the development of CRC. 
Additional evidence supporting a possible functional importance of FUT8 in 
colorectal cancer is the recent observation that micro RNA MiR-198 represses 
tumour growth and metastasis in colorectal cancer by targeting FUT8 (47). Our 
analysis of transcriptional data in publicly available datasets also revealed 
significantly increased expression of FUT8 in CRC (Fig 4). The finding that similar 
pattern of changes in FUT8 expression can be observed or inferred in both the 
tumour tissue and the antibody-producing B lymphocytes points to the importance 
of general mechanisms controlling fucosylation in CRC and implies that the same 
features of genetic makeup influence glyco-gene expression (and thereby 
glycosylation profile) in both the tumour tissue and in B cells. We recommend that 
attempts should be made to replicate the findings of this “hypothesis-generating” 
study in other datasets. In particular, the association between increased levels of 
core-fucose on neutral IgG glycans and CRC patients warrants further investigation 
given their potential therapeutic implications and translational potential. 
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Decreases in galactosylation and sialylation have been previously observed in a 
number of diseases, including in our recent large studies of inflammatory bowel 
disease (14) and systemic lupus erythematous (15). Thus, these glycan changes do 
not appear to be specific for CRC. However, the increase in core fucose on neutral 
glycans, with concurrent decrease of core-fucose on sialylated glycans has not been 
previously reported.  
In this study we have demonstrated significant differences in IgG glycome 
composition between CRC patients and controls. We were not able to detect these 
differences in historical samples (taken before CRC had developed in these patients). 
This could indicate that the changes are due to reverse causality (due to the disease 
process or treatment effects). However, it may also be due to inadequate study 
power in this small sub-study and so additional studies are required to investigate 
this further. Considering the functional relevance of IgG glycosylation for both 
tumour immunosurveilance and clinical efficacy of therapy with monoclonal 
antibodies, individual variation in IgG glycosylation may turn out to be important for 
prediction of disease course or the choice of therapy, thus warranting further, more 
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Table 2. IgG glycome composition in CRC patients and controls. Only the main derived traits 
describing glycome composition are shown. Directly measured glycan structures are available 
in Supplementary Table 2. 
G – galactose; F – fucose; B – bisecting GlcNAc, S – sialic acid 





  Cases (n = 760) Control (n = 538) p-value 
Age              
(median[IQR]) 52 (48-56) 53 (48-56) 0.274 
Sex              
(Men/Women) 
415 (54.6%) / 345 
(45.4%) 





133/172/271/184 94/139/211/103 0.836 
BMI             




524/197/39 517/6/15 6.50E-44 






G0 total 25.35 (20.67-29.24) 29.24 (24.62-34.74) 2.35 (1.95 - 2.82) 2.65E-23 2.39E-22 
G1 total 36.62 (34.87-38.09) 35.94 (34.49-37.39) 0.64 (0.55 - 0.74) 8.09E-10 3.64E-09 
G2 total 16.65 (14.41-19.62) 14.12 (11.71-16.78) 0.36 (0.30 - 0.44) 1.83E-30 6.59E-29 
F total 95.27 (94.42-95.97) 95.39 (94.40-96.11) 1.11 (0.97 - 1.28) 1.27E-01 1.53E-01 
F neutral 97.07 (96.38-97.66) 97.32 (96.50-97.97) 1.24 (1.08 - 1.43) 1.98E-03 3.57E-03 
F sialo 88.47 (86.69-89.79) 87.58 (85.39-89.29) 0.72 (0.62 - 0.84) 2.44E-05 5.85E-05 
B total 18.25 (16.81-20.22) 18.11 (16.49-20.02) 0.88 (0.76 - 1.01) 7.68E-02 9.87E-02 
B neutral 17.97 (16.35-20.54) 17.89 (16.07-19.93) 0.84 (0.73 - 0.97) 1.86E-02 2.91E-02 
B sialo 18.64 (16.48-21.33) 19.19 (16.99-21.71) 1.17 (1.01 - 1.35) 3.85E-02 5.13E-02 
S total 20.71 (18.64-23.62) 19.85 (17.39-21.96) 0.72 (0.62 - 0.83) 1.06E-05 2.73E-05 
S1 total 15.9 (14.07-18.07) 14.97 (12.94-16.74) 0.64 (0.54 - 0.75) 9.16E-09 3.66E-08 




Fig 1. UPLC analysis of the IgG glycome. Representative chromatogram showing 
separation of labelled IgG glycans into 24 chromatographic peaks is shown.   
 
Fig 2. IgG glycome composition in CRC patients and matching controls. IgG glycome 
was analysed in 760 patients with CRC and 538 matching controls. Main features of 
the IgG glycome are presented as box plots showing median values and 25% (box) 
and 75% (line) percentiles for patients and controls. Additional information is 
available in Table 2 and Supplementary Table 2. 
 
Fig 3. Classification of CrC patients using IgG glycans. Fig 3. ROC curve illustrating 
the performance of regularized logistic regression model in discrimination between 
CRC patients and healthy controls from SOCCS retrospective study. While models 
based only on age and gender did not show predictive power (dotted line), addition 
of glycan traits increased predictive power of model (solid line). 
 
Figure 4. Volcano plots showing changes in expression for the 20 candidate genes in 
three different datasets for colorectal carcinoma (see Materials and methods 
section). Names of the genes above cut-offs for the fold change and the statistical 
significance are indicated. One gene may correspond to multiple probe sets, each of 
them corresponding to a point on a graph. The log2 fold change refers to the ratio of 
expression in non-cancerous tissue to the expression in cancer tissue, which puts the 
genes with higher expression in cancer to the left and those with lower expression to 
the right. The position on the y-axis (-log10 p-value) corresponds to the statistical 
significance of the change, with higher significance positioned higher on the graph. 
 
 
 




